Indivior Pharmaceuticals, Inc.
At today's price, Indivior Pharmaceuticals, Inc. (INDV) is priced for +5.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Indivior is a specialty pharma focused on opioid-use-disorder treatment, and its story has narrowed to one drug: SUBLOCADE, a monthly buprenorphine injection that generated $856 million in 2025 and is growing fast [Source: Indivior FY2025 results, 8-K]. • The capital-allocation pivot is the theme: management is running the Indivior Action Agenda, discontinuing PERSERIS and OPVEE marketing and optimizing the international business for at least $150 million of annual cost savings in 2026 [Source
Is INDV overvalued? See what's priced in →
278 institutional managers reported holding INDV in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 51%. 76 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 11.9M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (7.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at INDV over the trailing three years: 2026: 3 buys totaling $31k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
INDV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2025-08-01 | +20.9% | +10.1% |
| 2025-10-31 | +16.3% | +21.7% |
| 2026-02-27 | -2.7% | +15.0% |
| 2026-05-01 | +10.1% | pending |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
INDV's latest 8-K filings: 2026-05-15 (items 5.02, 5.07); 2026-05-04 (items 7.01, 8.01, 9.01); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-03-17 (items 1.01, 1.02, 2.03, 3.02, 9.01); 2026-03-13 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.